Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
- PMID: 28232473
- DOI: 10.1136/gutjnl-2016-313589
Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis
Abstract
Objectives: Gastro-oesophageal reflux symptoms are common in the community, but there has been no definitive systematic review and meta-analysis of data from all studies to estimate their global prevalence, or potential risk factors for them.
Design: Medline, Embase and Embase Classic were searched (until September 2016) to identify population-based studies that reported the prevalence of gastro-oesophageal reflux symptoms in adults (≥15 years); gastro-oesophageal reflux was defined using symptom-based criteria or questionnaires. The prevalence was extracted for all studies, and according to the criteria used to define it. Pooled prevalence, according to study location and certain other characteristics, OR and 95% CIs were calculated.
Results: Of the 14 132 citations evaluated, 102 reported the prevalence of gastro-oesophageal reflux symptoms in 108 separate study populations, containing 460 984 subjects. Prevalence varied according to country (from 2.5% in China to 51.2% in Greece) and criteria used to define gastro-oesophageal reflux symptoms. When only studies using a weekly frequency of heart burn or regurgitation to define presence were considered, pooled prevalence was 13.3% (95% CI 12.0% to 14.6%). Prevalence was higher in subjects ≥50 years (OR 1.32; 95% CI 1.12 to 1.54), smokers (OR 1.26; 95% CI 1.04 to 1.52), non-steroidal anti-inflammatory drug (NSAID)/aspirin users (OR 1.44; 95% CI 1.10 to 1.88) and obese individuals (OR 1.73; 95% CI 1.46 to 2.06).
Conclusions: The prevalence of gastro-oesophageal reflux symptoms varied strikingly among countries, even when similar definitions were used to define their presence. Prevalence was significantly higher in subjects ≥50 years, smokers, NSAID users and obese individuals, although these associations were modest.
Keywords: GASTROESOPHAGEAL REFLUX DISEASE; META-ANALYSIS.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
Systematic review with meta-analysis: risk factors for Barrett's oesophagus in individuals with gastro-oesophageal reflux symptoms.Aliment Pharmacol Ther. 2021 May;53(9):968-976. doi: 10.1111/apt.16321. Epub 2021 Mar 11. Aliment Pharmacol Ther. 2021. PMID: 33705573
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2003;(4):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2003. Update in: Cochrane Database Syst Rev. 2010 Apr 14;(4):CD002300. doi: 10.1002/14651858.CD002300.pub2. PMID: 14583950 Updated.
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2002;(3):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2003;(4):CD002300. doi: 10.1002/14651858.CD002300. PMID: 12137654 Updated.
-
Prevalence of gastro-esophageal reflux-type symptoms in individuals with irritable bowel syndrome in the community: a meta-analysis.Am J Gastroenterol. 2012 Dec;107(12):1793-801; quiz 1802. doi: 10.1038/ajg.2012.336. Epub 2012 Oct 2. Am J Gastroenterol. 2012. PMID: 23032982
-
Cisapride treatment for gastro-oesophageal reflux in children.Cochrane Database Syst Rev. 2000;(3):CD002300. doi: 10.1002/14651858.CD002300. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(3):CD002300. doi: 10.1002/14651858.CD002300. PMID: 10908549 Updated.
Cited by
-
Elucidating shared biomarkers in gastroesophageal reflux disease and idiopathic pulmonary fibrosis: insights into novel therapeutic targets and the role of angelicae sinensis radix.Front Pharmacol. 2024 Feb 13;15:1348708. doi: 10.3389/fphar.2024.1348708. eCollection 2024. Front Pharmacol. 2024. PMID: 38414734 Free PMC article.
-
Effects of Osteopathic Visceral Treatment in Patients with Gastroesophageal Reflux: A Randomized Controlled Trial.J Clin Med. 2019 Oct 19;8(10):1738. doi: 10.3390/jcm8101738. J Clin Med. 2019. PMID: 31635110 Free PMC article.
-
Association Between Anxiety and Depression and Gastroesophageal Reflux Disease: Results From a Large Cross-sectional Study.J Neurogastroenterol Motil. 2018 Oct 1;24(4):593-602. doi: 10.5056/jnm18069. J Neurogastroenterol Motil. 2018. PMID: 30347938 Free PMC article.
-
Meta-analysis on the epidemiology of gastroesophageal reflux disease in China.World J Gastroenterol. 2022 Dec 7;28(45):6410-6420. doi: 10.3748/wjg.v28.i45.6410. World J Gastroenterol. 2022. PMID: 36533111 Free PMC article.
-
Whole-genome sequencing of esophageal adenocarcinoma in Chinese patients reveals distinct mutational signatures and genomic alterations.Commun Biol. 2018 Oct 24;1:174. doi: 10.1038/s42003-018-0182-8. eCollection 2018. Commun Biol. 2018. PMID: 30374464 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical